Anna Malovannaya
Baylor College of Medicine, TX·Biochemistry
Proteins do most of the work inside cells. In cancer, changes in which proteins are present, how they are chemically modified and which partners they bind can drive tumor growth.
- Fields
Biochemistry
Medicine & Clinical Research
Pharmacology
- Topics
proteomics
mass spectrometry
reverse phase protein array
- Grants
- 1 known grant, through Jun 2030
What they work on
- Provide antibody-based protein profiling for cancer researchers using a custom reverse phase protein array (RPPA), which measures many specific proteins across many samples.
- Measure protein levels, post-translational modifications and protein interactions with a suite of mass spectrometry assays, supported by study design, data analysis and interpretation.
- Coordinate multi-omic profiling of patient-derived xenograft (PDX) models, human tumors grown in mice, and human clinical samples across several cancer center core facilities.
- Develop new RPPA antibody panels for the tumor microenvironment and cancer immunology, and ultrasensitive mass spectrometry methods using a timsTOF Ultra2 instrument.
More about the research
Most cancer drugs target proteins. Measuring these protein changes can therefore reveal new drug targets and biomarkers that predict how patients will respond to treatment, sometimes better than DNA or RNA data alone. This grant supports a shared facility that provides protein measurement, known as proteomics, to cancer researchers at the Dan L Duncan Comprehensive Cancer Center (DLDCCC).
Why it matters
Detailed protein measurements from tumors, PDX models and patient samples could help cancer researchers identify new drug targets and biomarkers that predict which patients will respond to a therapy. New antibody panels for the tumor microenvironment and immune cells, along with more sensitive mass spectrometry, may extend these measurements to cancer immunology and to very small samples.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Alexey Nesvizhskii
University of Michigan, MI·Biochemistry
Improve interactome analysis by moving the REPRINT resource (SAINT scoring plus the CRAPome contaminant repository) to an MSFragger-based pipeline, expanding CRAPome, and refining scoring of protein–protein interactions from AP-MS data.
Jennifer Koblinski
Virginia Commonwealth University, VA·Medicine & Clinical Research
Develop more than 500 new patient-derived xenograft (PDX) models, patient tumors grown in mice, from the patient populations served by the cancer center.
Mark Chance
Case Western Reserve University, OH·Biochemistry
Provide proteomic and small-molecule analysis to cancer investigators, including protein identification, post-translational modification characterization, quantitative proteomics, protein interactome mapping and metabolomics, across collaborative and high-throughput service modes.
The school
Baylor College of Medicine: 38 labs on PI Pages, $881M a year on research, 115 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.